keyword
MENU ▼
Read by QxMD icon Read
search

SCLC

keyword
https://www.readbyqxmd.com/read/28345820/meta-analysis-of-serum-gastrin-releasing-peptide-precursor-as-a-biomarker-for-diagnosis-of-small-cell-lung-cancer
#1
Shui Ping Lv, Yi Wang, Lang Huang, Fei Wang, Jian Guo Zhou, Hu Ma
Background: The serum level of gastrin-releasing peptide precursor (proGRP) is generally? elevated in patients with small cell lung cancer (SCLC). However, the diagnostic sensitivity and specificity of serum proGRP in SCLC cases remains controversial. The study aimed to assess the diagnostic value of this biomarker by meta-analysis. Materials and Methods: The Cochrane, Clinical trials, Pubmed, Web of Science and Embase databases were searched and diagnostic values were calculated or extracted. Statistical analysis was accomplished with RevMan 5...
February 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28344664/current-understanding-and-approach-to-well-differentiated-lung-neuroendocrine-tumors-an-update-on-classification-and-management
#2
REVIEW
Talal Hilal
Neuroendocrine tumors (NETs) are rare neoplasms that can arise from any tissue. They are classified based on embryonic gut derivative (i.e. foregut, midgut and hindgut) with midgut tumors being the most common (e.g. gastrointestinal NET). The second most common category of NETs is that which arises from the lung. In fact, 25% of primary lung cancers are NETs, including small cell lung cancer (SCLC), which comprises 20% of all lung cancers. The remaining 5% are large cell neuroendocrine cancer (LCNEC, 3%), typical carcinoids (TCs, 1...
March 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28341109/phase-1-2-study-of-the-cd56-targeting-antibody-drug-conjugate-lorvotuzumab-mertansine-imgn901-in-combination-with-carboplatin-etoposide-in-small-cell-lung-cancer-patients-with-extensive-stage-disease
#3
Mark A Socinski, Frederic J Kaye, David R Spigel, Fred J Kudrik, Santiago Ponce, Peter M Ellis, Margarita Majem, Paul Lorigan, Leena Gandhi, Martin E Gutierrez, Dale Nepert, Jesus Corral, Luis Paz Ares
INTRODUCTION: This trial assessed the safety and efficacy of LM in combination with carboplatin/etoposide therapy compared to carboplatin/etoposide treatment alone in patients with previously untreated extensive-disease small-cell lung cancer (ED-SCLC). PATIENTS AND METHODS: A run-in phase 1 stage was used to determine the recommended phase 2 dose and characterize the dose-limiting toxicities of LM in combination with carboplatin/etoposide followed by LM alone in patients with CD56-positive solid tumors...
January 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28337388/the-clinical-significance-of-anti-mitotic-spindle-apparatus-antibody-msa-and-anti-centromere-antibody-aca-detected-in-patients-with-small-cell-lung-cancer-sclc
#4
Liming Tan, Yuhong Zhang, Yongqing Jiang, Hua Li, Juanjuan Chen, Feng Ming, Waimei Wang, Jianlin Yu, Tingting Zeng, Yongjian Tian, Yang Wu
PURPOSE: The project is aimed to detect anti-mitotic spindle apparatus antibody (MSA) and anti-centromere antibody (ACA) and explore the clinical value for the diagnosis of small cell lung cancer (SCLC), providing clinical evidence for molecular studies of SCLC. METHODS: 93 SCLC patients, 208 patients with other cancers and 50 healthy controls were enrolled in this study. MSA antibodies were detected by enzyme linked immunosorbent assay (ELISA). MSA, ACA and anti nuclear antibodies (ANA) were examined by indirect immuno-fluorescence (IIF)...
2017: American Journal of Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28337370/role-of-epidermal-growth-factor-receptor-in-lung-cancer-and-targeted-therapies
#5
REVIEW
Tie-Cheng Liu, Xin Jin, Yan Wang, Ke Wang
Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major forms of lung cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancers (SCLC), have responded effectively to chemo-, radiation and adjuvant-therapies. Tumor removal through surgery also appeared as a good therapeutic strategy. However, these therapies demonstrated unfavourable side-effects, and hence novel drugs targeting lung cancer emerged essential. Activation of epidermal growth factor receptor (EGFR)-tyrosine kinases is a key reason for lung cancer progression...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28332164/polymorphism-in-xrcc1-gene-modulates-survival-and-clinical-outcomes-of-advanced-north-indian-lung-cancer-patients-treated-with-platinum-based-doublet-chemotherapy
#6
Amrita Singh, Navneet Singh, Digambar Behera, Siddharth Sharma
Survival in lung cancer patients is genetically determined. Single nucleotide polymorphisms (SNPs) in DNA repair genes are observed to play a critical role in survival as DNA repair itself can behave as double-edged sword. We aim to explore the association of DNA repair gene XRCC1 in survival and clinical outcomes for North Indian population. Blood sample from patients diagnosed with lung cancer was taken. DNA isolation and genotyping were performed for the SNPs of XRCC1 gene. Further, patients were followed up through telephonic conversation after every 2 months for 3 years...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28326834/thoracic-radiation-therapy-could-give-survival-benefit-to-elderly-patients-with-extensive-stage-small-cell-lung-cancer
#7
Changchun An, Wang Jing, Yan Zhang, Sujing Liu, Haiyong Wang, Kunli Zhu, Li Kong, Hongbo Guo, Hui Zhu
AIM: To evaluate the effect of thoracic radiation therapy (TRT) in elderly patients (aged ≥65 years) with extensive-stage small-cell lung cancer (ES-SCLC). PATIENTS & METHODS: This study reviewed the records of 118 elderly patients with ES-SCLC (all with distant metastasis) through January 2006-December 2013. The patients were divided into either a chemotherapy (ChT)/TRT-combination group or a ChT-alone group. RESULTS: The median survival time and 3-year overall survival rates in the ChT/TRT group were significantly higher than those in the ChT-alone group (17...
February 24, 2017: Future Oncology
https://www.readbyqxmd.com/read/28325266/stage-i-small-cell-lung-cancer-a-new-potential-option-for-stereotactic-ablative-radiation-therapy-a-review-of-literature
#8
REVIEW
Filippo Alongi, Stefano Arcangeli, Berardino De Bari, Niccolò Giaj-Levra, Alba Fiorentino, Rosario Mazzola, Marco Trovò
Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC)...
April 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28314330/prognostic-factors-and-treatment-of-early-stage-small-cell-lung-cancer
#9
Lukas Käsmann, Louisa Bolm, Stefan Janssen, Dirk Rades
BACKGROUND/AIM: Only 0.1-0.17% of all lung cancer patients are diagnosed with stage I or II small cell lung cancer (SCLC). Radiochemotherapy remains the standard treatment for limited stage disease. This study focused on prognostic factors in early stage SCLC treated with radiochemotherapy. PATIENTS AND METHODS: Seven factors in eight patients with early stage SCLC were analyzed concerning the impact on overall survival, namely gender, age, Karnofsky performance score, N-category, UICC-stage, concurrent chemotherapy and prophylactic cranial irradiation (PCI)...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28302484/tspan12-promotes-chemoresistance-and-proliferation-of-sclc-under-the-regulation-of-mir-495
#10
Minting Ye, Ting Wei, Qiongyao Wang, Yanqin Sun, Ruixiang Tang, Linlang Guo, Weiliang Zhu
Studies have shown that TSPAN12 serves as an oncogenic gene or tumor suppressor depending on the types of cancer. However, its role in the drug resistance of small cell lung cancer (SCLC) is still unknown. In this study, we investigated whether TSPAN12 regulates chemoresistance, proliferation and tumor growth of SCLC under the regulation of miR-495 using two drug resistant cell lines. The results showed that down-regulation of TSPAN12 inhibited cells chemoresistance, proliferation and tumor growth. Besides, TSPAN12 elevation in SCLC specimens correlated with poor pathologic stage and shorter survival time...
March 13, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28302222/-advances-in-the-treatment-of-relapsed-small-cell-lung-cancer
#11
Bin Liu, Jianwen Qin, Jingmin Zhou
Small cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent years, treatment for relapsed SCLC is still a difficult problem in clinical field. In view of the serious resistance of recurrent SCLC to the existing chemotherapeutic drugs, the research on recurrent SCLC around the world is focused on the clinical trial of new drug development, optimization of chemotherapy regimen and target drug development...
March 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28299514/prognostic-and-predictive-value-of-circulating-tumor-cells-and-cxcr4-expression-as-biomarkers-for-a-cxcr4-peptide-antagonist-in-combination-with-carboplatin-etoposide-in-small-cell-lung-cancer-exploratory-analysis-of-a-phase-ii-study
#12
Ravi Salgia, R Waide Weaver, Michael McCleod, John R Stille, S Betty Yan, Stephanie Roberson, John Polzer, Amy Flynt, Eyas Raddad, Victoria L Peek, Sameera R Wijayawardana, Suzane L Um, Steve Gross, Mark C Connelly, Carrie Morano, Madeline Repollet, Renouard Sanders, Kurt Baeten, David D'Haese, David R Spigel
Background Circulating tumor cells (CTCs) and chemokine (C-X-C motif) receptor 4 (CXCR4) expression in CTCs and tumor tissue were evaluated as prognostic or predictive markers of CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE) versus CE in extensive-stage disease small cell lung cancer (ED-SCLC). Methods This exploratory analysis of a phase II study evaluated CXCR4 expression in baseline tumor tissue and peripheral blood CTCs and in post-treatment CTCs. Optimum cutoff values were determined for CTC counts and CXCR4 expression in tumors and CTCs as predictors of survival outcome...
March 15, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28296775/giant-hepatic-metastasis-in-a-patient-with-coin-like-small-cell-lung-carcinoma-incidentally-diagnosed-at-autopsy-a-case-report
#13
Decebal Fodor, Simona Gurzu, Anca Otilia Contac, Ioan Jung
RATIONALE: Encephalopathy is a rare complication of hepatic metastases. In this paper we present a case of a patient with lung cancer and metastatic-related giant hepatomegaly. PATIENT CONCERNS: A 78-year-old previously healthy male was admitted in the Emergency room in hepatic coma. DIAGNOSES: The abdominal CT scan examination revealed a huge liver filled with solid nodules. INTERVENTIONS: No interventions were performed...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28292730/chemotherapy-in-combination-with-cytokine-induced-killer-cell-transfusion-an-effective-therapeutic-option-for-patients-with-extensive-stage-small-cell-lung-cancer
#14
Jianmin Huang, Quancheng Kan, Lan, Xuan Zhao, Zhen Zhang, Shuangning Yang, Hong Li, Liping Wang, Li Xu, Zhe Cheng, Yi Zhang
BACKGROUND AND AIMS: In the past decade of clinical studies, the combination of chemotherapy with cytokine induced killer (CIK) cell transfusion has confirmed a promised efficacy in several types of cancer. CIK cells are a mixture of T lymphocytes, generated from peripheral blood mononuclear cells induced by multiple cytokines. This study was aimed to evaluate the clinical efficacy of chemotherapy combined with CIK- cell therapy in patients with extensive stage small cell lung cancer (ES SCLC)...
March 11, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28285690/the-cell-cell-interaction-between-tumor-associated-macrophages-and-small-cell-lung-cancer-cells-is-involved-in-tumor-progression-via-stat3-activation
#15
Toyohisa Iriki, Koji Ohnishi, Yukio Fujiwara, Hasita Horlad, Yoichi Saito, Cheng Pan, Koei Ikeda, Takeshi Mori, Makoto Suzuki, Hidenori Ichiyasu, Hirotsugu Kohrogi, Motohiro Takeya, Yoshihiro Komohara
OBJECTIVES: Small cell lung cancer (SCLC) is an aggressive tumor with a poor prognosis. It is well known that various stromal cells, including macrophages, play a role in tumor progression in several types of malignant tumors; however, the significance of tumor-associated macrophages (TAMs) in SCLC has not been fully elucidated. Signal transducer and activator of transcription 3 (STAT3) is a molecule well-known to be related to tumor progression. In the present study, we investigated the relationship of TAMs and SCLC cells to test the hypothesis that TAMs induce tumor progression in SCLC via STAT3 activation...
April 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28285684/dual-occurrence-of-alk-g1202r-solvent-front-mutation-and-small-cell-lung-cancer-transformation-as-resistance-mechanisms-to-second-generation-alk-inhibitors-without-prior-exposure-to-crizotinib-pitfall-of-solely-relying-on-liquid-re-biopsy
#16
Sai-Hong Ignatius Ou, Thomas K Lee, Lauren Young, Maria Y Fernandez-Rocha, Dean Pavlick, Alexa B Schrock, Viola W Zhu, Jeffrey Milliken, Siraj M Ali, Barbara J Gitlitz
Development of the acquired ALK G1202R solvent front mutation and small cell lung cancer (SCLC) transformation have both been independently reported as resistance mechanisms to ALK inhibitors in ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) patients but have not been reported in the same patient. Here we report an ALK+ NSCLC patient who had disease progression after ceritinib and then alectinib where an ALK G1202R mutation was detected on circulating tumor (ct) DNA prior to enrollment onto a trial of another next generation ALK inhibitor, lorlatinib...
April 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28283779/phase-ib-study-of-the-mitochondrial-inhibitor-me-344-plus-topotecan-in-patients-with-previously-treated-locally-advanced-or-metastatic-small-cell-lung-ovarian-and-cervical-cancers
#17
Jennifer R Diamond, Barbara Goff, Martin D Forster, Johanna C Bendell, Carolyn D Britten, Michael S Gordon, Hani Gabra, David M Waterhouse, Mark Poole, D Ross Camidge, Erika Hamilton, Kathleen M Moore
Background This multicenter, open-label, phase Ib study was designed to assess the safety, pharmacokinetics and preliminary efficacy of ME-344, a mitochondrial inhibitor, administered in combination with the topoisomerase I inhibitor, topotecan, in patients with previously treated, locally advanced or metastatic small cell lung (SCLC), ovarian and cervical cancers. Patients and methods In Part 1, patients received ME-344 10 mg/kg intravenously weekly on days 1, 8, 15 and 22 in combination with topotecan 4 mg/m(2) on days 1, 8, and 15 of a 28 day cycle...
March 10, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28283034/hypo-or-conventionally-fractionated-radiotherapy-combined-with-chemotherapy-in-patients-with-limited-stage-small-cell-lung-cancer
#18
Jing Zhang, Min Fan, Di Liu, Kuai-Le Zhao, Kai-Liang Wu, Wei-Xin Zhao, Zheng-Fei Zhu, Xiao-Long Fu
BACKGROUND: Previous data from our institution showed that hypofractionated thoracic radiotherapy (HypoTRT) with concurrent etoposide/platinum chemotherapy yielded favorable survival in patients with limited-stage small cell lung cancer (LS-SCLC). The present study retrospectively compared the survival outcomes, failure patterns and toxicities between groups of LS-SCLC patients treated with conventionally fractionated thoracic radiotherapy (ConvTRT) or HypoTRT combined with chemotherapy...
March 11, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28282545/nidogen-1-degraded-by-cathepsin-s-can-be-quantified-in-serum-and-is-associated-with-non-small-cell-lung-cancer
#19
Nicholas Willumsen, Cecilie L Bager, Diana J Leeming, Anne-Christine Bay-Jensen, Morten A Karsdal
Loss of basement membrane (BM) integrity is typically associated with cancer. Nidogen-1 is an essential component of the BM. Nidogen-1 is a substrate for cathepsin-S (CatS) which is released into the tumor microenvironment. Measuring nidogen-1 degraded by CatS may therefore have biomarker potential in cancer. The aim of this study was to investigate if CatS-degraded nidogen-1 was detectable in serum and a possible biomarker for cancer, a pathology associated with disruption of the BM. A competitive enzyme-linked immunosorbent assay (NIC) was developed with a monoclonal mouse antibody specific for a CatS cleavage site on human nidogen-1...
March 7, 2017: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/28280736/microrna-related-polymorphisms-in-pi3k-akt-mtor-pathway-genes-are-predictive-of-limited-disease-small-cell-lung-cancer-treatment-outcomes
#20
Wei Jiang, Wenjue Zhang, Lihong Wu, Lipin Liu, Yu Men, Jingbo Wang, Jun Liang, Zhouguang Hui, Zongmei Zhou, Nan Bi, Luhua Wang
The phosphoinositide-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays an important role in cancer progression and treatment, including that of small cell lung cancer (SCLC), a disease with traditionally poor prognosis. Given the regulatory role of microRNA (miRNA) in gene expression, we examined the association of single nucleotide polymorphisms (SNPs) at miRNA-binding sites of genes in the mTOR pathway with the prognosis of patients with limited-disease SCLC. A retrospective study was conducted of 146 patients with limited-disease SCLC treated with chemoradiotherapy...
2017: BioMed Research International
keyword
keyword
37726
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"